FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1848725235> ?p ?o ?g. }

• W1848725235 abstract "Candidaemia and other forms of invasive candidiasis (C/IC) in the intensive care unit are challenging conditions that are associated with high rates of mortality. New guidelines from the European Society for Clinical Microbiology and Infectious Diseases strongly recommend echinocandins for the first-line treatment of C/IC. Here, a cost-effectiveness model was developed from the United Kingdom perspective to examine the costs and outcomes of antifungal treatment for C/IC based on the European Society for Clinical Microbiology and Infectious Diseases guidelines.Costs and treatment outcomes with the echinocandin anidulafungin were compared with those for caspofungin, micafungin and fluconazole. The model included non-neutropenic patients aged ≥16 years with confirmed C/IC who were receiving intravenous first-line treatment. Patients were categorised as either a clinical success or failure (patients with persistent/breakthrough infection); successfully treated patients switched to oral therapy, while patients categorised as clinical failures switched to a different antifungal class. Other inputs were all-cause mortality at 6 weeks, costs of treatment-related adverse events and other medical resource utilisation costs. Resource use was derived from the published literature and from discussion with clinical experts. Drug-acquisition/administration costs were taken from standard United Kingdom costing sources.The model indicated that first-line anidulafungin could be considered cost-effective versus fluconazole (incremental cost-effectiveness ratio £813 per life-year gained) for the treatment of C/IC. Anidulafungin was cost-saving versus caspofungin and micafungin due to lower total costs and a higher rate of survival combined with a higher probability of clinical success.European Society for Clinical Microbiology and Infectious Diseases guidelines recommend echinocandins for the first-line treatment of C/IC; our model indicated that anidulafungin marries clinical effectiveness and cost-effectiveness.From the United Kingdom perspective, anidulafungin was cost-effective compared with fluconazole for the treatment of C/IC and was cost-saving versus the other echinocandins." @default.
• W1848725235 created "2016-06-24" @default.
• W1848725235 creator A5000138150 @default.
• W1848725235 creator A5020296118 @default.
• W1848725235 creator A5026321359 @default.
• W1848725235 creator A5029192232 @default.
• W1848725235 creator A5036641783 @default.
• W1848725235 creator A5039063558 @default.
• W1848725235 creator A5070109944 @default.
• W1848725235 creator A5088034168 @default.
• W1848725235 date "2015-10-26" @default.
• W1848725235 modified "2023-10-08" @default.
• W1848725235 title "Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis" @default.
• W1848725235 cites W1485519026 @default.
• W1848725235 cites W1911188526 @default.
• W1848725235 cites W1955515831 @default.
• W1848725235 cites W1974342169 @default.
• W1848725235 cites W2000147679 @default.
• W1848725235 cites W2020339002 @default.
• W1848725235 cites W2024285109 @default.
• W1848725235 cites W2054258448 @default.
• W1848725235 cites W2074503728 @default.
• W1848725235 cites W2080363965 @default.
• W1848725235 cites W2091750684 @default.
• W1848725235 cites W2105763273 @default.
• W1848725235 cites W2106569303 @default.
• W1848725235 cites W2121025359 @default.
• W1848725235 cites W2126319933 @default.
• W1848725235 cites W2127408422 @default.
• W1848725235 cites W2130921523 @default.
• W1848725235 cites W2136227603 @default.
• W1848725235 cites W2139545538 @default.
• W1848725235 cites W2141563676 @default.
• W1848725235 cites W2150428940 @default.
• W1848725235 cites W2162354270 @default.
• W1848725235 cites W2163845781 @default.
• W1848725235 cites W2166875150 @default.
• W1848725235 cites W2170945683 @default.
• W1848725235 doi "https://doi.org/10.1186/s12879-015-1143-1" @default.
• W1848725235 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4623895" @default.
• W1848725235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26503366" @default.
• W1848725235 hasPublicationYear "2015" @default.
• W1848725235 type Work @default.
• W1848725235 sameAs 1848725235 @default.
• W1848725235 citedByCount "11" @default.
• W1848725235 countsByYear W18487252352017 @default.
• W1848725235 countsByYear W18487252352018 @default.
• W1848725235 countsByYear W18487252352020 @default.
• W1848725235 countsByYear W18487252352021 @default.
• W1848725235 countsByYear W18487252352022 @default.
• W1848725235 countsByYear W18487252352023 @default.
• W1848725235 crossrefType "journal-article" @default.
• W1848725235 hasAuthorship W1848725235A5000138150 @default.
• W1848725235 hasAuthorship W1848725235A5020296118 @default.
• W1848725235 hasAuthorship W1848725235A5026321359 @default.
• W1848725235 hasAuthorship W1848725235A5029192232 @default.
• W1848725235 hasAuthorship W1848725235A5036641783 @default.
• W1848725235 hasAuthorship W1848725235A5039063558 @default.
• W1848725235 hasAuthorship W1848725235A5070109944 @default.
• W1848725235 hasAuthorship W1848725235A5088034168 @default.
• W1848725235 hasBestOaLocation W18487252351 @default.
• W1848725235 hasConcept C126322002 @default.
• W1848725235 hasConcept C16005928 @default.
• W1848725235 hasConcept C177713679 @default.
• W1848725235 hasConcept C190139176 @default.
• W1848725235 hasConcept C203014093 @default.
• W1848725235 hasConcept C2776222947 @default.
• W1848725235 hasConcept C2776376669 @default.
• W1848725235 hasConcept C2779020398 @default.
• W1848725235 hasConcept C2779320740 @default.
• W1848725235 hasConcept C2779548794 @default.
• W1848725235 hasConcept C2780161414 @default.
• W1848725235 hasConcept C2780402444 @default.
• W1848725235 hasConcept C2780651595 @default.
• W1848725235 hasConcept C71924100 @default.
• W1848725235 hasConceptScore W1848725235C126322002 @default.
• W1848725235 hasConceptScore W1848725235C16005928 @default.
• W1848725235 hasConceptScore W1848725235C177713679 @default.
• W1848725235 hasConceptScore W1848725235C190139176 @default.
• W1848725235 hasConceptScore W1848725235C203014093 @default.
• W1848725235 hasConceptScore W1848725235C2776222947 @default.
• W1848725235 hasConceptScore W1848725235C2776376669 @default.
• W1848725235 hasConceptScore W1848725235C2779020398 @default.
• W1848725235 hasConceptScore W1848725235C2779320740 @default.
• W1848725235 hasConceptScore W1848725235C2779548794 @default.
• W1848725235 hasConceptScore W1848725235C2780161414 @default.
• W1848725235 hasConceptScore W1848725235C2780402444 @default.
• W1848725235 hasConceptScore W1848725235C2780651595 @default.
• W1848725235 hasConceptScore W1848725235C71924100 @default.
• W1848725235 hasIssue "1" @default.
• W1848725235 hasLocation W18487252351 @default.
• W1848725235 hasLocation W18487252352 @default.
• W1848725235 hasLocation W18487252353 @default.
• W1848725235 hasLocation W18487252354 @default.
• W1848725235 hasOpenAccess W1848725235 @default.
• W1848725235 hasPrimaryLocation W18487252351 @default.
• W1848725235 hasRelatedWork W1687223343 @default.
• W1848725235 hasRelatedWork W1848725235 @default.
• W1848725235 hasRelatedWork W2048260460 @default.
• W1848725235 hasRelatedWork W2087216275 @default.

• next